Tweets
Tam et al . Increased CV risk in early RA abrogated with treat to target approach. @RheumNow #ACR22 Abstr#1649 https://t.co/i2iHyPoKf0 https://t.co/u0R00oolyP
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Reproductive concerns of adolescent patients with rheumatic disease
Abstract #129 #ACR22 @RheumNow
🤰Worried about effects of dx and meds on fertility and pregnancy
💊Concerns about which birth control to use
🩸Effects of dx. on menstruation
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Kimbrough et al. Comorbidities assoc serious infection in RA. Many! 26/55 comorbidities assoc serious infection. Number of comorbidities also assoc HR 1.16 (1.13-1.19) @RheumNow #ACR22 Abstr#1950 https://t.co/gnIlaJ037B https://t.co/6SR2Ej584w
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
RA asso w/ higher risk of lung cancer aHR 1.53, also in non-smokers aHR 1.66 🚬
Now this risk increases even more in pts w/ RA-ILD 🫁
aHR 3.06
No adjustment on occupation or non tobacco inhaled toxic exposure
https://t.co/41ibPD6S3b
Abs#1647 #ACR22 @RheumNow https://t.co/LNw792MYV0
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
Does Evusheld shield people living with rheumatic diseases? #ACR22
https://t.co/IutdoFxJUx https://t.co/FuKZEtpImm
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
Yazici et al. IA Lorecivivint in Knee OA. 56 week DB-RCT of single injection at time 0. Didn't work. Not for primary endpoint (Pain NRS) or any PRO. @RheumNow #ACR22 Abstr#1639 https://t.co/66KyJW1zVz
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Ultrasound and MRI have taught us a lot about PMR, but it's the power of PET/CT which illustrated the specific pathology of PMR in full color vision.
@drceowen #ACR22 @RheumNow https://t.co/N8hVjqpVwe
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Initial Fracture Risk Assessment - by age - remember: no FRAX scores <40 yo
Fracture re-assessments every 1-2 years with repeat BMD and risk stratifications
@RheumNow https://t.co/QlCVM1lDb0
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
BE OPTIMAL: BKZ in PsA Phase 3 RCT
Data at 52 wks 700+ completed study
ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA
PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA
No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA
Candida infections 7% BKZ, 0.7% ADA
https://t.co/MMjN1Aa3qf
Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
in patients under 40 yo, you cannot calculate #FRAX score, assess BMD and in children get also thoracolumbar xrays. Get repeat testing every 1-2 years #ACR22 @rheumnow https://t.co/CgsvzGKYuV
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
